![Albert Cha](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Albert Cha
Patrimonio netto: 231 792 $ in data 31/12/2025
Profilo
Albert Cha occupa la posizione di Managing Partner presso Frazier Management LLC. È anche nel consiglio di amministrazione di altre 6 società. In precedenza ha ricoperto la posizione di consulente presso Oracle Corp. e di Managing Partner presso Vivo Capital LLC. Ha conseguito una laurea e un diploma di laurea presso la Stanford University, un dottorato presso la David Geffen School of Medicine e un dottorato presso la University of California, Los Angeles.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 31/12/2024 | 1.087 ( 0% ) | 231 792 $ | 31/12/2025 |
Posizioni attive di Albert Cha
| Società | Posizione | Inizio |
|---|---|---|
| ASCENDIS PHARMA A/S | Presidente | 28/05/2021 |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States with an EBITDA of USD10 million - USD75 million. The firm focuses on sectors such as science, pharmaceuticals and healthcare services. It participates in mezzanine financing for late private/public opportunities, buyouts, recapitalizations, corporate carve-outs, seed, early and later stage with an investment size of USD50 million - USD400 million. | Investitore di Private Equity | 01/02/2021 |
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Provides novel plasma kallikrein inhibitors for treatment of diabetic macular oedema | Direttore/Membro del Consiglio | - |
Ceptaris Therapeutics, Inc.
 Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Direttore/Membro del Consiglio | - |
Neomend, Inc.
 Neomend, Inc. BiotechnologyHealth Technology Develops surgical wound healing products | Direttore/Membro del Consiglio | 29/01/2010 |
Precedenti posizioni note di Albert Cha
| Società | Posizione | Fine |
|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 03/10/2024 |
Vivo Capital LLC
 Vivo Capital LLC Investment ManagersFinance Vivo Capital invests in both public and private middle-market companies located across the globe. The firm targets companies operating in the fields of biotechnology, pharmaceutical, healthcare and life sciences. It provides financing for early stage, growth stage, buyouts, spin-offs, and restructurings. The firm also acquires controlling interest. | Investitore di Private Equity | 30/11/2020 |
| VYNE THERAPEUTICS INC. | Direttore/Membro del Consiglio | 19/03/2019 |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Direttore/Membro del Consiglio | 07/09/2018 |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Albert Cha
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 30 |
|---|---|
Oracle Corp.
 Oracle Corp. Provides cloud based enterprise applications and infrastructure technologies & license, hardware and IT services | |
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States with an EBITDA of USD10 million - USD75 million. The firm focuses on sectors such as science, pharmaceuticals and healthcare services. It participates in mezzanine financing for late private/public opportunities, buyouts, recapitalizations, corporate carve-outs, seed, early and later stage with an investment size of USD50 million - USD400 million. | Finance |
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital invests in both public and private middle-market companies located across the globe. The firm targets companies operating in the fields of biotechnology, pharmaceutical, healthcare and life sciences. It provides financing for early stage, growth stage, buyouts, spin-offs, and restructurings. The firm also acquires controlling interest. | Finance |
Angiogenix, Inc.
 Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic solutions for chronic vascular diseases | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Develops novel therapeutic approaches for cancer and other diseases | Health Technology |
TRIA Beauty, Inc.
 TRIA Beauty, Inc. Medical SpecialtiesHealth Technology Manufactures and retails hair removal and skincare devices through online | Health Technology |
Aspreva Pharmaceuticals Corp.
 Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Biodel, Inc.
 Biodel, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
BioForm Medical, Inc.
 BioForm Medical, Inc. Medical SpecialtiesHealth Technology Develops technology for soft and hard tissue augmentation | Health Technology |
Carbylan Therapeutics, Inc.
 Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of molecule protease inhibitors | Health Technology |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
APT Pharmaceuticals, Inc.
 APT Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a drug development company | Health Technology |
AirXpanders, Inc.
 AirXpanders, Inc. Medical SpecialtiesHealth Technology Develops medical devices for women who require tissue expansion for breast reconstruction | Health Technology |
NextWave Pharmaceuticals, Inc.
 NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder | Health Technology |
Minerva Surgical, Inc.
 Minerva Surgical, Inc. Develops medical devices for women's healthcare | |
Vicept Therapeutics, Inc.
 Vicept Therapeutics, Inc. Develops dermatologic therapeutic products | |
Health360, Inc.
 Health360, Inc. Provides health services | |
Aclaris Therapeutics, Inc.
 Aclaris Therapeutics, Inc. Develops and commercializes novel drug candidates for immuno-inflammatory diseases | |
Menlo Therapeutics, Inc.
 Menlo Therapeutics, Inc. Engages in development and commercialization of serlopitant products | |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Neomend, Inc.
Neomend, Inc. BiotechnologyHealth Technology Develops surgical wound healing products | Health Technology |
Essentialis, Inc.
 Essentialis, Inc. Pharmaceuticals: OtherHealth Technology Develops therapeutic products in curing metabolic diseases | Health Technology |
Ascendis Pharma A/S
 Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops drug candidates | Health Technology |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Provides novel plasma kallikrein inhibitors for treatment of diabetic macular oedema | |
Medley Health, Inc.
 Medley Health, Inc. Provides marketing and communications services | |
Biohaven Pharmaceutical Holding Co. Ltd.
 Biohaven Pharmaceutical Holding Co. Ltd. Operates as a biopharmaceutical company that develops drugs to treat neurological and neuropsychiatric diseases | |
KalVista Pharmaceuticals, Inc.
 KalVista Pharmaceuticals, Inc. Manufactures and markets small molecule protease inhibitors for diseases | |
Dermatology Innovation Forum | |
Frazier Life Sciences Management LP
 Frazier Life Sciences Management LP Frazier Life Sciences generally seeks long-term capital appreciation through making investments in and creating biopharmaceutical companies in the global healthcare sector and developing novel therapeutics near value inflection points. The firm attempts to employ a disciplined investment style and achieve diversification within the global healthcare sector, with the goal of creating attractive risk-adjusted returns. |
